I found the paper Lower risk for cardiovascular mortality in oral 1-hydroxy vitamin D3 users in a haemodialysis population of great interest [1]. We have found a reduction in levels of the inflammatory risk markers for cardiovascular disease, sCRP, MMP2 and most especially of MMP9, in apparently healthy Bangladeshi subjects, with higher vitamin D status and also following supplementation of vitamin D-deficient subjects over a year. In addition, raised MMP9 was a better marker of risk for clinically evident cardiovascular disease than sCRP in our study group [2]. The question that arises, therefore, is whether circulating MMP9, MMP2 or sCRP levels might be available on your study subjects and, if so, whether they may prove to be reduced in users of 1
-hydroxy vitamin D3?
Conflict of interest statement. None declared.
Centre for Diabetes and Metabolic Medicine [Bart's and the London Queen Mary School of Medicine and Dentistry] Royal London Hospital London E1 1BB UK Email: bboucher{at}doctors.org.uk
References
|